A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA

NCT02193945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2015-07-09

No results posted yet for this study

Summary

The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (VMA) with JETREA® (ocriplasmin), including incidence, time to onset and resolution of anatomy and symptoms.

Conditions

  • Symptomatic Vitreomacular Adhesion (VMA)

Sponsors & Collaborators

  • ThromboGenics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02193945 on ClinicalTrials.gov